Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Down 0% - Should You Sell?

Key Points

• DMAA shares were essentially flat in mid-day trading at approximately $10.745, with volume reaching 25,141 shares—242% above the average session volume.
• Analyst sentiment remains negative: Weiss Ratings reiterated a “Sell (D)” rating, and MarketBeat reports a consensus “Sell” rating from the sole analyst covering the stock.
• Several institutional investors recently acquired or increased positions in DMAA, while the company continues operating as a blank-check company seeking a business combination in the U.S. pharmaceutical manufacturing sector.

Shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Get Free Report) were down 0% during mid-day trading on Monday . The company traded as low as $10.74 and last traded at $10.7450. Approximately 25,141 shares changed hands during mid-day trading, an increase of 242% from the average session volume of 7,348 shares. The stock had previously closed at $10.75.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of Drugs Made In America Acquisition in a report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of "Sell".

Drugs Made In America Acquisition Stock Down 0.0%

The firm's 50 day moving average price is $10.68 and its two-hundred day moving average price is $10.58.

Hedge Funds Weigh In On Drugs Made In America Acquisition

A number of institutional investors have recently added to or reduced their stakes in DMAA. Mercuria Capital Strategies LLC acquired a new position in shares of Drugs Made In America Acquisition in the fourth quarter worth about $7,511,000. Boothbay Fund Management LLC purchased a new position in Drugs Made In America Acquisition in the second quarter valued at about $5,814,000. Quarry LP grew its stake in Drugs Made In America Acquisition by 1,595.5% during the 4th quarter. Quarry LP now owns 266,551 shares of the company's stock valued at $2,765,000 after purchasing an additional 250,830 shares in the last quarter. Governors Lane LP grew its stake in Drugs Made In America Acquisition by 2,132.1% during the 4th quarter. Governors Lane LP now owns 250,000 shares of the company's stock valued at $2,594,000 after purchasing an additional 238,800 shares in the last quarter. Finally, L1 Global Manager Pty Ltd acquired a new stake in Drugs Made In America Acquisition during the 4th quarter valued at approximately $2,075,000.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp NASDAQ: DMAA is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company's stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source